Bradley Foster & Sargent Inc. CT lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 64,349 shares of the biopharmaceutical company’s stock after acquiring an additional 5,154 shares during the period. Bradley Foster & Sargent Inc. CT owned approximately 4,923.41% of Gilead Sciences worth $5,214,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Mitsubishi UFJ Asset Management UK Ltd. purchased a new stake in Gilead Sciences in the 3rd quarter worth approximately $3,402,000. Swiss National Bank boosted its position in Gilead Sciences by 0.9% in the 3rd quarter. Swiss National Bank now owns 4,817,324 shares of the biopharmaceutical company’s stock worth $390,300,000 after purchasing an additional 41,800 shares in the last quarter. Greenwood Capital Associates LLC boosted its position in Gilead Sciences by 162.5% in the 3rd quarter. Greenwood Capital Associates LLC now owns 80,209 shares of the biopharmaceutical company’s stock worth $6,499,000 after purchasing an additional 49,653 shares in the last quarter. Sunbelt Securities Inc. boosted its position in Gilead Sciences by 22.6% in the 3rd quarter. Sunbelt Securities Inc. now owns 7,150 shares of the biopharmaceutical company’s stock worth $579,000 after purchasing an additional 1,317 shares in the last quarter. Finally, Bank of Hawaii boosted its position in Gilead Sciences by 24.3% in the 3rd quarter. Bank of Hawaii now owns 42,506 shares of the biopharmaceutical company’s stock worth $3,444,000 after purchasing an additional 8,323 shares in the last quarter. Institutional investors and hedge funds own 76.11% of the company’s stock.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down $3.49 during trading on Wednesday, reaching $83.80. The company had a trading volume of 12,790,000 shares, compared to its average volume of 8,580,000. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $89.54. The stock has a market cap of $109,440.00, a PE ratio of 9.53, a price-to-earnings-growth ratio of -1.96 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue for the quarter was down 13.2% on a year-over-year basis. During the same period last year, the business posted $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
In other Gilead Sciences news, insider John F. Milligan sold 220,000 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP James R. Meyers sold 100,000 shares of the stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the completion of the sale, the executive vice president now directly owns 102,715 shares in the company, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. Insiders sold a total of 503,333 shares of company stock worth $37,834,758 in the last ninety days. 1.30% of the stock is owned by corporate insiders.
Several equities research analysts have commented on GILD shares. William Blair restated a “buy” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Mizuho set a $77.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the stock from $73.67 to $94.00 in a research note on Thursday, November 30th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the company’s stock. Gilead Sciences has an average rating of “Buy” and an average price target of $85.58.
ILLEGAL ACTIVITY NOTICE: “Bradley Foster & Sargent Inc. CT Has $5.21 Million Holdings in Gilead Sciences, Inc. (GILD)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/31/bradley-foster-sargent-inc-ct-has-5-21-million-holdings-in-gilead-sciences-inc-gild.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.